TapImmune, Aeras team on TB vaccine

TapImmune has signed a deal with non-profit development group Aeras for preclinical work on a tuberculous vaccine. TapImmune's technology is designed to make vaccines more effective by boosting antigen presentation through the use of the Transporter of Antigen Processing (TAP). Financial terms of the deal were not disclosed. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.